Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | JAK2 | O60674 | 1/20 | 0.73 |
| ▸ | RAB9A | P51151 | 1/20 | 0.73 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.58 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22196871 | 0.85 | LMNA (1.00) | ALDH1A1LMNAJAK2RAB9AEPHX2 | |
| SCHEMBL24667562 | 0.84 | ALDH1A1 (0.55) | ALDH1A1LMNAJAK2RAB9AEPHX2 | |
| SCHEMBL19808524 | 0.84 | ALDH1A1 (0.55) | ALDH1A1LMNAJAK2RAB9AEPHX2 | |
| SCHEMBL9743900 | 0.84 | HDAC3 (0.64) | ALDH1A1LMNAJAK2RAB9AEPHX2 | |
| SCHEMBL12846029 | 0.82 | ALDH1A1 (0.53) | ALDH1A1LMNAJAK2RAB9AEPHX2 | |
| SCHEMBL18007753 | 0.82 | ALDH1A1 (0.53) | ALDH1A1LMNAJAK2RAB9AEPHX2 | |
| SCHEMBL23884204 | 0.81 | EPHX2 (0.61) | ALDH1A1LMNAJAK2RAB9AEPHX2 | |
| SCHEMBL3374604 | 0.81 | JAK2 (0.51) | ALDH1A1LMNAJAK2RAB9AEPHX2 | |
| SCHEMBL5994123 | 0.80 | ALDH1A1 (0.50) | ALDH1A1LMNAJAK2RAB9AEPHX2 | |
| SCHEMBL5805076 | 0.79 | ALDH1A1 (0.50) | ALDH1A1LMNAJAK2RAB9AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111647165-B | Preparation method and application of dendritic supramolecular polymer based on cyclodextrin | 天津科技大学 | 2021-09-28 | — | — | CN | claimed |
| CN-111647165-A | Preparation method and application of dendritic supramolecular polymer based on cyclodextrin | 天津科技大学 | 2020-09-11 | — | — | CN | claimed |
| US-20240132479-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2024-04-25 | — | — | US | disclosed |
| WO-2023125751-A1 | DIA-BASED QUANTITATIVE CHEMICAL PROTEOMICS TARGET SCREENING METHOD | 北京大学 | 2023-07-06 | — | — | WO | disclosed |
| US-11655238-B2 | MMPL3 inhibitors, compositions and uses thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-05-23 | — | — | US | disclosed |
| US-11655238-B2 | MMPL3 inhibitors, compositions and uses thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-05-23 | — | — | US | disclosed |
| US-11420944-B2 | Voltage-dependent t-type calcium channel blocker | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-08-23 | — | — | US | disclosed |
| WO-2022165198-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20220017492-A1 | MMPL3 INHIBITORS, COMPOSITIONS AND USES THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-01-20 | — | — | US | disclosed |
| CN-111647165-B | Preparation method and application of dendritic supramolecular polymer based on cyclodextrin | 天津科技大学 | 2021-09-28 | — | — | CN | disclosed |
| US-20210134398-A1 | Combinatorial Chemistry Computational System and Enhanced Selection Method | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-05-06 | — | — | US | disclosed |
| US-6995285-B2 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050267215-A1 | ATP binding cassette transporter 1 (ABCA-1); increases high density lipoprotein (HDL) levels; use treating coronary artery disease; N-phenyl-N-(2-hydroxy-cyclohexyl)-2-(1,3,3-trimethyl-bicyclo[2.2.1]hept-2-ylamino)acetamide for example | CV THERAPEUTICS, INC. | 2005-12-01 | — | — | US | disclosed |
| US-20050043353-A1 | Cinchona-alkaloid-based catalysts, and asymmetric alcoholysis of cyclic anhydrides using them | BRANDEIS UNIVERSITY | 2005-02-24 | — | — | US | disclosed |
| WO-2004110609-A2 | CATALYTIC ASYMMETRIC DESYMMETRIZATION OF PROCHIRAL AND MESO CYCLIC ANHYDRIDES | BRANDEIS UNIVERSITY (US) | 2004-12-23 | — | — | WO | disclosed |
| US-6713650-B2 | ELEVATES ATP BINDING CASSETTE TRANSPORTER 1 EXPRESSION THEREBY INCREASING EFFLUX OF CHOLESTEROL FROM CELLS BY ACTIVE TRANSFER INTO HIGH DENSITY LIPOPROTEINS | CV THERAPEUTICS, INC. | 2004-03-30 | — | — | US | disclosed |
| EP-1377283-A2 | COMPOUNDS OF THE FORMULA R1-X-Y-Z-NR2R3 AS ABCA-1 ELEVATING AGENTS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2004-01-07 | — | — | EP | disclosed |
| WO-2003103651-A1 | COMPOUNDS OF THE FORMU;A R1-X-Y-Z-NR2R3 AS ABCA-1 ELEVATING AGENTS AGAINST CAD OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20020082257-A1 | ABCA-1 Elevating compounds | CV THERAPEUTICS, INC. | 2002-06-27 | — | — | US | disclosed |
| WO-2002046141-A2 | COUMPOUNDS OF THE FORMULA R1-X-Y-Z-NR2R3 AS ABCA-1 ELEVATING AGENTS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267215-A1 | ATP binding cassette transporter 1 (ABCA-1); increases high density lipoprotein (HDL) levels; use treating coronary artery disease; N-phenyl-N-(2-hydroxy-cyclohexyl)-2-(1,3,3-trimethyl-bicyclo[2.2.1]hept-2-ylamino)acetamide for example | ABCD3, ABCF1, ABCC2 | ALDH1A1 459/4885LMNA 1082/4885JAK2 4884/4885 |
| US-11655238-B2 | MMPL3 inhibitors, compositions and uses thereof | TIMP3, AFG3L2, MMP3 | ALDH1A1 4205/4885LMNA 762/4885JAK2 3766/4885 |
| US-20220017492-A1 | MMPL3 INHIBITORS, COMPOSITIONS AND USES THEREOF | TIMP3, AFG3L2, MMP3 | ALDH1A1 4205/4885LMNA 762/4885JAK2 3766/4885 |
| US-20050043353-A1 | Cinchona-alkaloid-based catalysts, and asymmetric alcoholysis of cyclic anhydrides using them | CA7, CA9, CA1 | ALDH1A1 47/4885LMNA 321/4885JAK2 3844/4885 |
| US-11420944-B2 | Voltage-dependent t-type calcium channel blocker | CACNA1I, CACNA1G, CACNA1E | ALDH1A1 3247/4885LMNA 1556/4885JAK2 2009/4885 |
| US-20020082257-A1 | ABCA-1 Elevating compounds | ABCD3, ABCE1, ABCB4 | ALDH1A1 399/4885LMNA 1603/4885JAK2 4873/4885 |
| US-20240132479-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | CUTA, DCXR, PLOD3 | ALDH1A1 349/4885LMNA 555/4885JAK2 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.